Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mira Keyes

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Medical Oncology (Northwood, London, England)|December 8, 2017
Large-scale DNA organization is a prognostic marker of breast cancer survivalMartial Guillaud, Qian Ye, Sam Leung, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 16, 2011
Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonistsHoward Huaihan Pai, Tom Pickles, Mira Keyes, et al.
Brachytherapy|February 2, 2015
Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapyIngrid Spadinger, Jackson Chu, Maryam Afsari Golshan, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 19, 2022
2022 American Society of Clinical Oncology (ASCO): Meeting highlightsPeter C Black, Nazanin Fallah-Rad, Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|February 6, 2010
Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?Anna Thompson, Mira Keyes, Tom Pickles, et al.
Brachytherapy|March 15, 2011
The effect of loose versus stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapyChristopher Herbert, W James Morris, Jeremy Hamm, et al.
International Journal of Radiation Oncology, Biology, Physics|February 13, 2009
Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-upMira Keyes, Stacy Miller, Veronika Moravan, et al.
Brachytherapy|August 10, 2010
Quadrant dosimetry as a predictor of biochemical relapse in 125I prostate brachytherapyIngrid Spadinger, W James Morris, Mira Keyes, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 14, 2012
Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: a population-based cohort studyChristopher Herbert, W James Morris, Mira Keyes, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2013
Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survivalAndrea C Lo, W James Morris, Vincent Lapointe, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Medical Oncology (Northwood, London, England)|December 8, 2017
Large-scale DNA organization is a prognostic marker of breast cancer survivalMartial Guillaud, Qian Ye, Sam Leung, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 16, 2011
Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonistsHoward Huaihan Pai, Tom Pickles, Mira Keyes, et al.
Brachytherapy|February 2, 2015
Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapyIngrid Spadinger, Jackson Chu, Maryam Afsari Golshan, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 19, 2022
2022 American Society of Clinical Oncology (ASCO): Meeting highlightsPeter C Black, Nazanin Fallah-Rad, Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|February 6, 2010
Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?Anna Thompson, Mira Keyes, Tom Pickles, et al.
Brachytherapy|March 15, 2011
The effect of loose versus stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapyChristopher Herbert, W James Morris, Jeremy Hamm, et al.
International Journal of Radiation Oncology, Biology, Physics|February 13, 2009
Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-upMira Keyes, Stacy Miller, Veronika Moravan, et al.
Brachytherapy|August 10, 2010
Quadrant dosimetry as a predictor of biochemical relapse in 125I prostate brachytherapyIngrid Spadinger, W James Morris, Mira Keyes, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 14, 2012
Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: a population-based cohort studyChristopher Herbert, W James Morris, Mira Keyes, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2013
Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survivalAndrea C Lo, W James Morris, Vincent Lapointe, et al.
Pageof 10